STX 1400
Alternative Names: STX-1400Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator Scribe Therapeutics
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action APOC3 protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hypertriglyceridaemia
Most Recent Events
- 25 Nov 2024 Preclinical trials in Hypertriglyceridaemia in USA (Parenteral) (Scribe Therapeutics Pipeline, December 2024)
- 25 Nov 2024 Pharmacodynamics data from a preclinical study in hypertriglyceridemia released by Scribe Therapeutics
- 16 Nov 2024 Pharmacodynamics data from preclinical studies in Hypertriglyceridemia presented at the American Heart Association Scientific Sessions 2024 (AHA-2024)